Nicole Evans
Physician Assistant · Honolulu, HINPI 1013686906
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,958, 2.6 times the $757 reported in 2023. Among physician assistant clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $39.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$689
- Jazz Pharmaceuticals Inc.$650
- Argenx US, Inc.$388
- Pfizer$209
- Inspire Medical Systems, Inc.$166
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,38597%
- Education$1223%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $1,001 |
| AstraZeneca | 7 | $689 |
| Jazz Pharmaceuticals Inc. | 8 | $650 |
| Argenx US, Inc. | 5 | $388 |
| Pfizer | 6 | $209 |
| Inspire Medical Systems, Inc. | 3 | $166 |
| SK Life Science, Inc. | 6 | $163 |
| Eisai Inc. | 5 | $135 |
| TG Therapeutics, Inc. | 1 | $135 |
| Lundbeck LLC | 5 | $126 |
| Amgen | 1 | $120 |
| Livanova USA, Inc. | 1 | $109 |
| Neurelis, Inc. | 5 | $107 |
| Amneal Pharmaceuticals LLC | 3 | $74 |
| UCB, Inc. | 2 | $66 |
| Novartis | 2 | $45 |
| Catalyst Pharmaceuticals, Inc. | 2 | $45 |
| CSL Behring | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| Cala Health, Inc. | 1 | $21 |
| Tanabe Pharma America, Inc. | 1 | $19 |
| EMD Serono, Inc. | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Acorda Therapeutics, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XYWAV$485
- ULTOMIRIS$385
- BRIUMVI$135
- BOTOX$128
- VYVGART$125
- UBRELVY$125
- Inspire$124
- SOLIRIS$122
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$109
- VYVGART HYTRULO$102
How this compares
$4,507 in reported general payments places this provider in the 90th percentile of 246 physician assistant providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 88 | $128,956 |
| BotoxOnabotulinumtoxina | 45 | $56,492 |
| FycompaPerampanel | 36 | $46,718 |
| BriviactBrivaracetam | 23 | $39,697 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $22,703 |
| XcopriCenobamate | 14 | $19,390 |
| UbrelvyUbrogepant | 12 | $18,894 |
| Emgality PenGalcanezumab-Gnlm | 20 | $17,127 |
| QuliptaAtogepant | 15 | $16,088 |
| Clobazam | 18 | $1,840 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 64 | $1,426 |
| Memantine Hcl | 49 | $1,413 |
| Levetiracetam | 35 | $1,196 |
| Gabapentin | 56 | $1,188 |
| Lacosamide | 31 | $1,127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $209 | $128,95688 claims |
| AbbVieBotox, Ubrelvy, Qulipta | $1,001 | $91,47472 claims |
| Eisai Inc.Fycompa | $135 | $46,71836 claims |
| UCB, Inc.Briviact | $66 | $39,69723 claims |
| SK Life Science, Inc.Xcopri | $163 | $19,39014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 246 physician assistant providers in Hawaii.
Other physician assistant in Honolulu
- Eric YukumotoHonolulu$41K
- Dorothy MauriceHonolulu$39K
- Joycelyn ChunHonolulu$11K
- Rachel InouyeHonolulu$11K
- Timothy HowardHonolulu$10K
- Tiffany TranHonolulu$6K
- Jamie TamayoseHonolulu$5K
- Rory RuskovichHonolulu$5K
- Ayanna JoseHonolulu$4K
- Christopher AcreeHonolulu$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.